A 2-part Phase 1/2 Open-label Trial on ODM-212

A 2-part Phase 1/2 Open-label Trial on ODM-212

Conditions: Mesothelioma; Pancreatic Cancer; NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: Drug: ODM-212; Drug: Ipilimumab and nivolumab; Drug: Gemcitabine and nab-paclitaxel; Drug: sotorasib
Sponsors: Orion Corporation, Orion Pharma
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 5, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments